Industry Research Reports: Therapeutic Class Overview: New Avatars of Microbes Super Bugs a Growing Threat Worldwide

Novel approaches to treat infection is growing as the need is urgent! Misuse/overuse of antibiotics accelerated antimicrobial resistance (AMR) and has resulted in the emergence of super bugs which are posing life threatening challenges world wide. Many of the advances in medical treatment like cancer therapy; organ transplants etc. would go waste if the ability to fight infections during the treatment were not available. If that fails, the gains made in life-improving modern medical advantages will be lost creating a situation of - one step forward two step back. Novel approaches are immediately required to combat these super infections warranting need for new classes of antibiotics and other preventive/therapeutic approaches.

In this report we discuss

* The evolution and global dissemination of AMR

* Unmet need in the critical setting esp. Gram Negative infections and CRE.

* Pipeline of novel targets being used to develop new drugs to treat infections and resistance.

* Pipeline of select drugs in mid and late clinical stage of development

* Alarming Facts about AMR

* Steps being taken by the regulatory authorities WW to address the issue and encourage novel therapeutics in this therapy area.

* Developing Countries- /ROW -- Trends in pathogens and resistance

* Role of diagnostics and preventive approach.

Table of Content

* Introduction- Evolution and global dissemination of Anti Micorbial Resistance (AMR)

- How has the Problem Manifested to Such an Alarming Level?
- Microbial Evolution has Outpaced Innovation!-
- Hitch Hiking and Globe Trotting by Bad Bugs-
- Unmet need in the critical setting -
- Running Out of Drugs to Treat Serious Gram-Negative Infections
- Carbapenem-resistant Enterobacteriaceae (CREs)
- Evolution of CRE -
- Spreading the Bug

* Need of the Hour- New Targets= New Antibiotic Class

- Pipeline of novel targets being used to develop new drugs to treat infections and resistance.
- Pipeline of select drugs in mid and late clinical stage of development

* Alarming Facts about AMR - CDC Alerts

* Action by Regulatory Bodies -to Accelerate Drug development and Threat Awareness-

* The GAIN Act
* Breakthrough Therapies Designation

Europe

* Draft guidance Expedited Programs for Serious Conditions--Drugs and Biologics
* Strategic Research Agenda
* Developing Countries- /ROW -- Trends in pathogens and resistance
* Role of diagnostics and preventive approach

To order this report:

Email: support@researchonglobalmarkets.com

US: +1 800 986 6819

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE: Researchonglobalmarkets.com

Blog: blog.researchonglobalmarkets.com